Research Analysts Offer Predictions for Pacira Pharmaceuticals Inc’s Q4 2018 Earnings (PCRX)

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) – Stock analysts at Piper Jaffray Companies raised their Q4 2018 earnings per share (EPS) estimates for Pacira Pharmaceuticals in a research note issued on Monday, January 7th. Piper Jaffray Companies analyst D. Amsellem now expects that the company will earn $0.15 per share for the quarter, up from their prior forecast of $0.14. Piper Jaffray Companies has a “Buy” rating and a $55.00 price objective on the stock.

Several other brokerages also recently commented on PCRX. JMP Securities lifted their target price on Pacira Pharmaceuticals from $56.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, November 1st. Needham & Company LLC set a $60.00 target price on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 1st. HC Wainwright lifted their target price on Pacira Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a research note on Friday, November 2nd. Mizuho lifted their target price on Pacira Pharmaceuticals to $46.00 and gave the stock a “neutral” rating in a research note on Monday, November 5th. Finally, JPMorgan Chase & Co. lifted their target price on Pacira Pharmaceuticals from $45.00 to $50.00 and gave the stock a “neutral” rating in a research note on Friday, November 2nd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $54.25.

PCRX stock opened at $38.29 on Thursday. The company has a quick ratio of 7.83, a current ratio of 8.66 and a debt-to-equity ratio of 0.95. Pacira Pharmaceuticals has a twelve month low of $26.95 and a twelve month high of $55.00. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -66.02 and a beta of 1.57.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.40. The firm had revenue of $83.45 million during the quarter, compared to the consensus estimate of $79.87 million. Pacira Pharmaceuticals had a positive return on equity of 2.74% and a negative net margin of 1.30%. The business’s revenue was up 23.9% compared to the same quarter last year. During the same period last year, the company earned $0.11 earnings per share.

In other Pacira Pharmaceuticals news, VP Lauren Bullaro Riker sold 1,000 shares of Pacira Pharmaceuticals stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $54.35, for a total value of $54,350.00. Following the completion of the transaction, the vice president now directly owns 11,474 shares of the company’s stock, valued at approximately $623,611.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David M. Stack sold 15,000 shares of Pacira Pharmaceuticals stock in a transaction on Thursday, November 15th. The shares were sold at an average price of $47.39, for a total value of $710,850.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 164,748 shares of company stock valued at $8,032,891. 5.90% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in PCRX. Partner Fund Management L.P. raised its holdings in Pacira Pharmaceuticals by 82.5% in the 2nd quarter. Partner Fund Management L.P. now owns 3,110,213 shares of the company’s stock valued at $99,682,000 after acquiring an additional 1,405,605 shares in the last quarter. Macquarie Group Ltd. raised its holdings in Pacira Pharmaceuticals by 49.4% in the 2nd quarter. Macquarie Group Ltd. now owns 2,321,125 shares of the company’s stock valued at $74,392,000 after acquiring an additional 768,011 shares in the last quarter. Vanguard Group Inc raised its holdings in Pacira Pharmaceuticals by 7.2% in the 3rd quarter. Vanguard Group Inc now owns 3,641,417 shares of the company’s stock valued at $178,976,000 after acquiring an additional 243,213 shares in the last quarter. Vanguard Group Inc. raised its holdings in Pacira Pharmaceuticals by 7.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,641,417 shares of the company’s stock valued at $178,976,000 after acquiring an additional 243,213 shares in the last quarter. Finally, Castleark Management LLC acquired a new position in Pacira Pharmaceuticals in the 3rd quarter valued at $11,086,000. 97.84% of the stock is owned by hedge funds and other institutional investors.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Recommended Story: Purposes and Functions of the Federal Reserve

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply